Back to results
US 2026/0085111 A1Published application
Slit2 related compositions and methods
AssigneeEverest Medicines (Singapore) Pte. Ltd.
InventorsJie ZHAO, Shan HE, Wei Jennifer YANG, He LI
Life of this patent
Estimating the term…
Abstract
The antibodies bind to SLIT2 and related substitution mutants, including their manufacture and use.
Claims54
An antibody comprising:
- a heavy chain comprising complementarity determining regions (CDR) CDR-H1 comprising amino acid sequence of SEQ ID NO:
- 1;
- CDR-H2 comprising amino acid sequence of SEQ ID NO:
- 2;
- and CDR-H3 comprising amino acid sequence of SEQ ID NO:
- 3, respectively and having a specific binding activity to human SLIT2 and/or blocking activity to ROBO2;
- and
- a light chain comprising CDR-L1 comprising amino acid sequence of SEQ ID NO:
- 4 or 7;
- CDR-L2 comprising amino acid sequence of SEQ ID NO:
- 5;
- and CDR-L3 comprising amino acid sequence of SEQ ID NO:
- 6 and having a specific binding activity to human SLIT2 and/or blocking activity to ROBO2.
10 more elements
A recombinant antibody capable of modulating ROBO2 and SLIT2 interaction, wherein the antibody comprises:
- a heavy chain comprising an amino acid sequence at least 85% identical to any of the amino acid sequences of SEQ ID NOS:
- 12, 44-47 and having a specific binding activity to human SLIT2 and/or blocking activity to ROBO2, wherein the heavy chain includes CDR-H1, CDR-H2 and CDR-H3 defined by SEQ ID NOS-3, respectively;
- and
- a) a light chain comprising an amino acid sequence at least 85% identical to any of the amino acid sequences of SEQ ID NO:
- 13, 48-49 and having a specific binding activity to human SLIT2 and/or blocking activity to ROBO2, wherein the light chain variable domain includes CDR-L1, CDR-L2 and CDR-L3 defined by SEQ ID NOS:4-6, respectively, or
- b) a light chain comprising an amino acid sequence at least 85% identical to any of the amino acid sequences of SEQ ID NOS:
- 50-51 and having a specific binding activity to human SLIT2 and/or blocking activity to ROBO2, wherein the light chain variable domain includes CDR-L1, CDR-L2 and CDR-L3 defined by SEQ ID NOS:7, 5 and 6, respectively.
4 more elements
An isolated nucleic acid molecule encoding variable regions of an antibody, comprising:
- a nucleotide sequence encoding a heavy chain variable region of any of SEQ ID NOS:
- 10, 32-35;
- and
- a nucleotide sequence encoding a light chain variable region of any of SEQ ID NOS:
- 11, 36-39.
2 more elements
An isolated nucleic acid molecule encoding antibody heavy and light chains, comprising:
- a nucleotide sequence encoding a heavy chain of any of SEQ ID NOS:
- 14, 52-55;
- and
- a nucleotide sequence encoding a light chain of any of SEQ ID NOS:
- 15, 56-59.
2 more elements
Dependencies are inferred from the claim text.